NMDA receptor antagonists ketamine and Ro25-6981 inhibit evoked release of glutamate in vivo in the subiculum

Preclinical and clinical data have identified ketamine, a non-selective NMDAR (N-methyl-D-aspartate receptor) antagonist, as a promising medication for patients who do not respond to treatment with monoamine-based antidepressants. Moreover, unlike the current monoamine-based antidepressants, ketamin...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Stan, T L, Alvarsson, A, Branzell, N, Sousa, V C, Svenningsson, P
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2014
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4080320/
https://ncbi.nlm.nih.gov/pubmed/24893066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tp.2014.39
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg